surmount-1 tirzepatide trial obesity without diabetes SURMOUNT-4 results just published in @JAMA_current 🛑Stopping #tirzepatide leads to regain of the majority of the lost weight. Is this a surprising result ⁉️ No #Obesity is a chronic disease and requires With respect to the SURMOUNT-MAINTAIN

In June 2025, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England launched the Yellow Card Biobank initiative to investigate genetic susceptibility to rare adverse drug reactions, including incretin-related pancreatitis

The primary endpoint was the mean change in HbA1c from baseline to week 52 for tirzepatide relative to insulin lispro ( 4.7 SURPASS J-mono trial in Japan In Japan, the SURPASS J-mono trial enrolled 636 Japanese adults with type 2 diabetes (age 20 years) who discontinued oral monotherapy or were treatment-naive due to hyperglycemia ( 4.8 SURPASS J-combo trial in Japan The SURPASS J-combo trial included 443 Japanese adults with type 2 diabetes (age 20 years, BMI 23 kg/m 2 , inadequately controlled HbA1c), who received tirzepatide 5 mg, 10 mg, 15 mg in addition to oral antidiabetic drugs for 3 months

Should I drink protein shakes on tirzepatide

Phase 3 trial results expected in the coming months

We relied on brand as a proxy for target dose